logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

On November 12th, PW MEDTECH (01358) spent 1.034 million Hong Kong dollars to repurchase 1 million shares.

date
20:02 12/11/2024
avatar
GMT Eight
PwC Holdings Limited (01358) announced on November 12, 2024 that it will spend HK$103.4 million to repurchase its shares.
PW MEDTECH (01358) announced that on November 12, 2024, it will spend 1.034 million Hong Kong dollars to repurchase 1 million shares at a repurchase price of 1.03-1.04 Hong Kong dollars per share.
Related Articles
US Stock
Apple Inc. (AAPL.US) launches "Creator Studio" subscription package: bundling creative apps such as Final Cut Pro for a monthly fee of $12.99.
HK Stock
LAEKNA-B (02105): The US Food and Drug Administration has accepted the clinical trial application for the new drug LAE118.
China Stock
Shanghai Longcheer Technology's H-share issue price is not more than HK$31 per share.
Apple Inc. (AAPL.US) launches "Creator Studio" subscription package: bundling creative apps such as Final Cut Pro for a monthly fee of $12.99.
US Stock
LAEKNA-B (02105): The US Food and Drug Administration has accepted the clinical trial application for the new drug LAE118.
HK Stock
Shanghai Longcheer Technology's H-share issue price is not more than HK$31 per share.
China Stock
RECOMMEND
Institutions Bullish On Hong Kong Stocks As Spring Rally Builds; Domestic And Foreign Capital Increase ETF Allocations
Institutions Bullish On Hong Kong Stocks As Spring Rally Builds; Domestic And Foreign Capital Increase ETF Allocations
icon
13/01/2026
The Sword Over Hong Kong Stocks: IPO Peaks And Unlocking Waves
The Sword Over Hong Kong Stocks: IPO Peaks And Unlocking Waves
icon
13/01/2026
Learning From History: The AI Investment Wave Likely To End This Year, But The Fed May Shield U.S. Stocks
Learning From History: The AI Investment Wave Likely To End This Year, But The Fed May Shield U.S. Stocks
icon
13/01/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.